SCUBE1 and Irisin Relation in Bladder Cancer

Year 2023, Volume: 2 Issue: 1, 26 - 30, 30.03.2023

Diler Us Altay

Abstract

Bladder Cancer (BC) is a urogenital system disease with a frequency of approximately 11.000 new cases. The major risk factors of BC are smoking and exposure to industrial carcinogens. The diagnosis and monitoring of BC largely consist of invasive tests involving periodic cystoscopy. This method is known as the gold standard although this is a trustworthy method the procedure is highly disturbing for the cancer patient and causes comorbidity. That’s why; non-invasive diagnostic methods continue to be researched. Signal Peptide CUB Epidermal Growth Factor 1 Containing Protein (SCUBE1) is a member of the SCUBE family. SCUBE1 is often closely associated with pathological conditions such as thrombus, atherosclerotic plaque, inflammation, and hypoxia-related disorders. Many recent studies have focused on the expression and function of the SCUBE family in cancer. Studies of the SCUBE family have demonstrated the potential to develop as a diagnostic or prognostic biomarker in cancer. Irisin is an adipocytokine produced by proteolytic cleavage of the fibronectin type III domain-containing protein 5 (FNDC5). There are many studies examining the relationship between irisin and cancer. Although SCUBE1 and irisin have been evaluated as early diagnosis biomarkers of bladder cancer in many studies, no study evaluating the parameters together has been found. In the future, multicenter studies evaluating SCUBE1 and irisin parameters together are needed for the early diagnosis of bladder cancer in people who smoke and are exposed to various chemicals.

Keywords

SCUBE1, Irisin, bladder cancer

Mesane Kanserinde SCUBE1 ve İrisin İlişkisi

Abstract

Mesane Kanseri (MK) yaklaşık 11,000 yeni vaka sıklığına sahip ürogenital sistem hastalığıdır. Mesane kanserinin başlıca risk faktörleri sigara içmek ve endüstriyel kanserojenlere maruz kalmaktır. MK'nın teşhisi ve izlenmesi büyük ölçüde periyodik sistoskopiyi içeren invaziv testlerden oluşur. Bu yöntem altın standart olarak bilinir, güvenilir bir yöntem olmasına rağmen işlem hasta için oldukça rahatsız edicidir ve komorbiditeye neden olur. Bu nedenle non-invaziv tanı yöntemleri araştırılmaya devam etmektedir. Sinyal Peptit CUB Epidermal Büyüme Faktörü 1 İçeren Protein (SCUBE1), SCUBE ailesinin bir üyesidir. SCUBE1 genellikle trombüs, aterosklerotik plak, inflamasyon ve hipoksi ile ilişkili bozukluklar gibi patolojik durumlarla yakından ilişkilidir. Son zamanlarda yapılan birçok çalışma da SCUBE ailesinin kanserdeki ekspresyonu ve işlevine odaklanılmaktadır. SCUBE ailesi ile ilgili yapılan çalışmalar, kanserde teşhis veya prognostik bir biyobelirteç olarak gelişme potansiyeli olduğunu göstermiştir. İrisin, Fibronektin Tip III Domainini İçeren 5. proteinin (FNDC5) proteolitik bölünmesiyle üretilen bir adipomiyokindir. İrisin ve kanser arasındaki ilişkiyi inceleyen birçok araştırma vardır. SCUBE1 ve irisin, birçok çalışmada mesane kanseri için erken tanı biyobelirteci olarak değerlendirilmesine rağmen parametreleri birlikte değerlendiren bir çalışmaya rastlanılmamıştır. Gelecekte, sigara içen ve çeşitli kimyasalara maruz kalan kişilerde erken mesane kanseri tanısı için SCUBE1 ve irisin parametrelerini birlikte değerlendiren çok merkezli çalışmalara ihtiyaç duyulmaktadır.

Keywords

scube1, mesane kanseri, irisin, SCUBE1, Irisin

References

• 1. Honoré Jean Gabriel Berthé, Dramane Cissé, Moussa Salifou Diallo, Amadou Kassogué, Alkadri Diarra, Mamadou Tidiani Coulibaly, Mamadou Lamine Diakité, Modibo Coulibaly, Mory Koné. Bladder Cancer: idemiological, Clinical and Histopathological Aspects at the University Hospital Point G, Mali, Open Journal of Urology. 2021;11: 343-350.
• 2. Cumberbatch MG, Rota M, Catto JWF, La Vecchia C. The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks. Eur Urol 2016; 70:458–466.
• 3. Stern MC, Lin J, Figueroa JD, et al. Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the International Consortium of Bladder Cancer. Cancer Res 2009; 69:6857–6864.
• 4. Zeegers MP, Goldbohm RA, van den Brandt PA.A prospective study on active and environmental tobacco smoking and bladder cancer risk (The Netherlands). Cancer Causes Control. 2002;13(1):83-90.
• 5. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306(7):737-45.
• 6. Véronique Phé, Bladder Cancer in Neurogenic Patients, World Journal of Urology. 2022; 40:1895–1896.
• 7. Mentese A, Demır S, Ozer Yaman S, Us Altay D, Fidan E, Karaguzel E. Can serum SCUBE1 levels be useful in the diagnosis of bladder cancer? Exp Clin Med. 2022;39(2): 525-529.
• 8. Sankiewicz A, Guszcz T, Mena-Hortelano R, Zukowski K, Gorodkiewicz E. Podoplanin serum and urine concentration in transitional bladder cancer. Cancer Biomark. 2016;16: 343-50.
• 9. Tokarzewicz A, Guszcz T, Onopiuk A, Kozlowski R, Gorodkiewicz E. Utility of cystatin C as a potential bladder tumour biomarker confirmed by surface plasmon resonance technique. Indian J Med Res. 2018;147: 46-50.
• 10. Wang Z, Li H, Chi Q, Qiu Y, Li X, Xin L. Clinical significance of serological and urological levels of bladder cancer-specific antigen-1 (BLCA-1) in bladder cancer. Med Sci Monit. 2018; 24:3882-724.
• 11. Guszcz T, Szymańska B, Kozlowski R, Lukaszewski Z, Laskowski P, Gorodkiewicz E. Plasma aromatase as a sensitive and selective potential biomarker of bladder cancer and its role in tumorigenesis. Oncol Lett. 2020;19(1): 562-8.
• 12. Topcu TO, Kavgaci H, Ozdemir F, Aksoy A, Erdem D, Mentese A, Yaman H, Tufan G, Orem A, Aydin F.Elevated Serum Levels of SCUBE1, a Marker for Coagulation, in Patients with Breast Cancer. Tohoku J Exp Med. 2015;237(2):127-32.
• 13. Ikushima S, Ono R, Fukuda K, Sakayori M, Awano N, Kondo K. Trousseau's syndrome: cancer-associated thrombosis. Jpn J Clin Oncol. 2016;46(3):204-8.
• 14. Cekic AB, Gonenc Cekic O, Aygun A, Pasli S, Yaman Ozer S, Caner Karahan S, Turedi S, Acar S, Tatli O, Yulug E, Turkmen, Suha. The Diagnostic Value of ischemia-modified albumin (IMA) and signal peptide-CUB-EGF domain-containing protein-1 (SCUBE-1) in an Experimental Model of Strangulated Mechanical Bowel Obstruction.J Invest Surg. 2022; 35(2):450-456.
• 15. Mentese A, Fidan E, Uzun Sumer A, Karahan SC, Sonmez M, Us Altay D, Kavgacı H, Alver A. Is SCUBE 1 a new biomarker for gastric cancer ?, Cancer Biomarkers 2012; 11(5):191-195 .
• 16. Karagüzel E, Menteşe A, Kazaz IO, Demir S, Örem A, Okatan AE, et al. SCUBE1: a promising biomarker in renal cell cancer. Int Braz J Urol. 2017;43: 638-43.
• 17. Kumar, S.; Prajapati, K.S.;Gupta, S. The Multifaceted Role of Signal Peptide‐CUB‐EGF Domain Containing Protein (SCUBE) in Cancer. Int. J. Mol. Sci. 2022;23:10577.
• 18. Zhang D, Tan X, Tang N, Huang F, Chen Z, Shi G.Review of research on the role of irisin in tumors. Onco Targets Ther 2020;13:4423–4430.
• 19. Liu J, Song N, Huang Y, Chen Y.Irisin inhibits pancreatic cancer cell growth via the AMPK-mTOR pathway. Sci Rep. 2018;8(1):15247.
• 20. Moon HS, Mantzoros CS. Regulation of cell proliferation and malignant potential by irisin in endometrial, colon, thyroid and esophageal cancer cell lines. Metabolism. 2014;63:188-93.
• 21. Us Altay D, Keha EE, Ozer Yaman S, Ince I, Alver A, Erdogan B, et al. Investigation of the expression of irisin and some cachectic factors in mice with experimentally induced gastric cancer. QJM. 2016;109:785-90.
• 22. Kuloglu T, Celik O, Aydin S, Hanifi Ozercan I, Acet M, Aydin Y, et al. Irisin immunostaining characteristics of breast and ovarian cancer cells. Cell Mol Biol (Noisy-le-grand). 2016;62:40-4.
• 23. Provatopoulou X, Georgiou GP, Kalogera E, Kalles V, Matiatou MA, Papapanagiotou I, et al. Serum irisin levels are lower in patients with breast cancer: association with disease diagnosis and tumor. BMC Cancer. 2015;11:15:898.
• 24. Aydin S, Kuloglu T, Ozercan MR, Albayrak S, Aydin S, Bakal U, et al. Irisin immunohistochemistry in gastrointestinal system cancers. Biotech Histochem. 2016;91:242-50.
• 25. Gaggini M, Cabiati M, Del Turco S, Navarra T, De Simone P, Filipponi F, et al. Increased FNDC5/Irisin expression in human hepatocellular carcinoma. Peptides. 2017;88:62-66.
• 26. Shao L, Li H, Chen J, Song H, Zhang Y, Wu F, et al. Irisin suppresses the migration, proliferation, and invasion of lung cancer cells via inhibition of epithelial-to-mesenchymal transition. Biochem Biophys Res Commun. 2017;485:598-605.
• 27. Vliora M, Nintou E, Karligiotou E, Ioannou LG, Grillo E, Mitola S, Flouris AD. Implication of Irisin in Different Types of Cancer: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2022;1:23(17):9971.
• 28. Kim JS, Galvão DA, Newton RU, Gray E, Taaffe DR.Exercise-induced myokines and their effect on prostate cancer. Nat Rev Urol. 2021;18(9):519-542.
• 29. Esawy MM, Abdel-Samd KM. The diagnostic and prognostic roles of serum irisin in bladder cancer.Curr Probl Cancer 2020; 44(4):100529.
• 30. Taken K, Aslan R,Eryilmaz R, Alp HH, Huyut Z, Dönmez Mİ. Serum irisin is a novel biomarker for bladder cancer detection. Int Urol Nephrol. 2022;54(1):55-61.